Prestige Consumer Healthcare Inc. $PBH Shares Bought by JPMorgan Chase & Co.

Key Points

• JPMorgan Chase & Co. increased its stake in Prestige Consumer Healthcare by 30.1%, buying 106,224 shares to hold 459,228 shares (about 0.96% of the company) valued at roughly $28.66 million, while other major institutions like Dimensional and Allspring also raised positions, leaving institutional ownership at 99.95%.
• Prestige missed quarterly expectations, reporting $1.14 EPS vs. $1.16 expected and $283.44M revenue vs. $286.93M expected; the company set FY2026 guidance at 4.54 EPS, and analysts have a consensus Hold rating with a $76.50 price target.
• Insider activity: VP Jeffrey Zerillo sold 1,000 shares on Feb 11 (a 2.38% reduction of his stake); corporate insiders collectively own about 1.40% of the stock.

JPMorgan Chase & Co. grew its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 30.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 459,228 shares of the company's stock after buying an additional 106,224 shares during the quarter. JPMorgan Chase & Co. owned about 0.96% of Prestige Consumer Healthcare worth $28,656,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. Dimensional Fund Advisors LP grew its holdings in Prestige Consumer Healthcare by 4.8% during the third quarter. Dimensional Fund Advisors LP now owns 2,591,744 shares of the company's stock worth $161,723,000 after acquiring an additional 119,459 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in Prestige Consumer Healthcare by 4.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,592,375 shares of the company's stock valued at $100,893,000 after acquiring an additional 70,376 shares during the period. Westwood Holdings Group Inc. boosted its position in shares of Prestige Consumer Healthcare by 2.4% during the 2nd quarter. Westwood Holdings Group Inc. now owns 881,908 shares of the company's stock worth $70,420,000 after purchasing an additional 20,626 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Prestige Consumer Healthcare by 19.1% during the 2nd quarter. Bank of America Corp DE now owns 721,371 shares of the company's stock worth $57,601,000 after purchasing an additional 115,459 shares in the last quarter. Finally, Raymond James Financial Inc. grew its stake in shares of Prestige Consumer Healthcare by 15.7% during the 3rd quarter. Raymond James Financial Inc. now owns 637,932 shares of the company's stock worth $39,807,000 after purchasing an additional 86,373 shares during the period. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Prestige Consumer Healthcare

In related news, VP Jeffrey Zerillo sold 1,000 shares of the stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $65.93, for a total value of $65,930.00. Following the sale, the vice president directly owned 41,048 shares of the company's stock, valued at approximately $2,706,294.64. This represents a 2.38% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

PBH has been the subject of a number of research analyst reports. Jefferies Financial Group cut their price target on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a "hold" rating for the company in a report on Friday, January 30th. Weiss Ratings reissued a "hold (c)" rating on shares of Prestige Consumer Healthcare in a report on Thursday, January 22nd. Three analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $76.50.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $62.77 on Tuesday. The stock has a fifty day moving average price of $65.77 and a 200 day moving average price of $63.24. The stock has a market cap of $2.97 billion, a PE ratio of 16.61, a P/E/G ratio of 1.92 and a beta of 0.41. Prestige Consumer Healthcare Inc. has a 1 year low of $57.25 and a 1 year high of $89.37. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.93 and a current ratio of 3.11.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last posted its earnings results on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing the consensus estimate of $1.16 by ($0.02). Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The firm had revenue of $283.44 million during the quarter, compared to analyst estimates of $286.93 million. During the same period last year, the company posted $1.22 EPS. The firm's revenue for the quarter was down 2.4% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. Sell-side analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women's health.

Key brands in Prestige's portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women's health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.